Who are Travoprost/ Timolol/ Azopt/ Brimonidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/travoprost-timolol-azopt-brimonidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Travoprost/ Timolol/ Azopt/ Brimonidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Travoprost/ Timolol/ Azopt/ Brimonidine (Travoprost/ Timolol/ Azopt/ Brimonidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist. Area: Ophthalmology.

phase 3 Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist Prostaglandin F2α receptor, Beta-adrenergic receptor, Carbonic anhydrase, Alpha-2 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Travoprost/ Timolol/ Azopt/ Brimonidine (Travoprost/ Timolol/ Azopt/ Brimonidine) — Singapore Eye Research Institute. Travoprost is a prostaglandin F2α analogue that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Azopt is a carbonic anhydrase inhibitor that decreases intraocular pressure by reducing aqueous humor production. Brimonidine is an α2-adrenergic receptor agonist that decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Travoprost/ Timolol/ Azopt/ Brimonidine TARGET	Travoprost/ Timolol/ Azopt/ Brimonidine	Singapore Eye Research Institute	phase 3	Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist	Prostaglandin F2α receptor, Beta-adrenergic receptor, Carbonic anhydrase, Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist class)

Singapore Eye Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Travoprost/ Timolol/ Azopt/ Brimonidine — Competitive Intelligence Brief. https://druglandscape.com/ci/travoprost-timolol-azopt-brimonidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab